Engineered red Opto-mGluR6 Opsins, a red-shifted optogenetic excitation tool, an in vitro study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0311102 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Hoda Shamsnajafabadi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran. Hauptthemen laut MEDLINE: Optogenetics. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Medical Research Development, National Center for Genetic Engineering and Biotechnology.
Abstract (Originalsprache)
Degenerative eye diseases cause partial or complete blindness due to photoreceptor degeneration. Optogenetic gene therapy is a revolutionary technique combining genetics and optical methods to control the function of neurons. Due to the inherent risk of photochemical damage, the light intensity necessary to activate Opto-mGluR6 surpasses the safe threshold for retinal illumination. Conversely, red-shifted lights pose a significantly lower risk of inducing such damage compared to blue lights. We designed red-shifted Opto-mGluR6 photopigments with a wide, red-shifted working spectrum compared to Opto-mGluR6 and examined their excitation capability in vitro. ROM19, ROM18 and ROM17, red-shifted variants of Opto-mGluR6, were designed by careful bioinformatics/computational studies. The predicted molecules with the best scores were selected, synthesised and cloned into the pAAV-CMV-IRES-EGFP vector. Expression of constructs was confirmed by functional assessment in engineered HEK-GIRK cells. Spectrophotometry and patch clamp experiments demonstrated that the candidate molecules were sensitive to the desired wavelengths of the light and directly coupled light stimuli to G-protein signalling. Herein, we introduce ROM17, ROM18 and ROM19 as newly generated, red-shifted variants with maximum excitation red-shifted of ~ 40nm, 70 nm and 126 nm compared to Opto-mGluR6.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
- Laser & Plasma Research Institute, Shahid Beheshti University, Tehran, Iran.
- Department of Physiology and Pharmacology, Pasteur Institute of Iran (IPI), Tehran, Iran.
- Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Molecular Biomarkers Nano-imaging Laboratory, Brigham & Women's Hospital, Department of Radiology, Harvard Medical School, Boston, Massachusetts, United States of America.
ORCID-Profile: Hoda Shamsnajafabadi, Zahra-Soheila Soheili
Förderung
- National Institute for Medical Research Development
- National Center for Genetic Engineering and Biotechnology
Zitieren
APA
Shamsnajafabadi, H., Soheili, Z. S., Sadeghi, M., Samiee, S., Ghasemi, P., Zibaii, M. I., Gholami Pourbadie, H., Ahmadieh, H., Ranaei Pirmardan, E., Salehi, N., Samiee, D., & Kashanian, A. (2024). Engineered red Opto-mGluR6 Opsins, a red-shifted optogenetic excitation tool, an in vitro study. PLOS ONE. https://doi.org/10.1371/journal.pone.0311102
Vancouver
Shamsnajafabadi H, Soheili ZS, Sadeghi M, Samiee S, Ghasemi P, Zibaii MI, et al. Engineered red Opto-mGluR6 Opsins, a red-shifted optogenetic excitation tool, an in vitro study. PLOS ONE. 2024. doi:10.1371/journal.pone.0311102
BibTeX
@article{Shamsnajafabadi2024,
author = {Shamsnajafabadi, Hoda and Soheili, Zahra-Soheila and Sadeghi, Mehdi and Samiee, Shahram and Ghasemi, Pouria and Zibaii, Mohammad Ismail and Gholami Pourbadie, Hamid and Ahmadieh, Hamid and Ranaei Pirmardan, Ehsan and Salehi, Najmeh and Samiee, Dorsa and Kashanian, Ali},
title = {Engineered red Opto-mGluR6 Opsins, a red-shifted optogenetic excitation tool, an in vitro study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0311102}
}
EUVIMED